ğŸ‘ å°åˆ†å­|æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©

---
[TOC]

---
* Hagit Achdout, Anthony Aimon, Elad Bar-David, Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics, doi: https://doi.org/10.1101/2020.10.29.339317 [å¤§è§„æ¨¡ç­›é€‰å‘ç°æŠ—3CLå¼‚å–¹å•‰éª¨æ¶hitçš„é¢„å°ç‰ˆæ–‡ç« pdf](./å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©/2020.10.29.339317v3.full.pdf)
* Glaser J, Sedova A, Galanie S, et al. Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor. ACS Pharmacol Transl Sci. 2022 Apr 4;5(4):255-265. [å¯¹å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©è¿›ä¸€æ­¥ç»“æ„æ”¹é€ å¹¶è§£å‡ºå¤åˆç‰©æ™¶ä½“ç»“æ„çš„æ–‡çŒ®pdf](./å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©/pt2c00026.pdf)
* Rossetti GG, Ossorio MA, Rempel S, et al. Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. Sci Rep. 2022 Feb 15;12(1):2505. [å–¹å•‰é…®éª¨æ¶ç±»ä¼¼ç‰©çš„æŠ—3CLæ´»æ€§ä»¥åŠå¤åˆç‰©æ™¶ä½“ç»“æ„æ–‡ç« pdf](./å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©/s41598-022-06306-4.pdf)
* Chodera J, Lee A A, London N, et al. Crowdsourcing drug discovery for pandemics[J]. Nature Chemistry, 2020, 12(7): 581-581. [COVID Moonshotç»„ç»‡çš„ç®€ä»‹åŠæ¥æºçš„æ–‡ç« pdf](./å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©/s41557-020-0496-2.pdf)
* Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020 Oct 7;11(1):5047. [Fragment crystal structure with 3CL protein pdf](./å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©/s41467-020-18709-w.pdf)


* [Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro](https://www.biorxiv.org/content/10.1101/2022.08.10.503531v1.abstract)
![](å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©/å°åˆ†å­æ–°å† ç—…æ¯’3CLè›‹ç™½å¼‚å–¹å•‰éª¨æ¶åŒ–åˆç‰©_2022-12-19-22-02-14.png)